Oppenheimer analyst Jay Olson downgraded CinCor Pharma to Perform from Outperform without a price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CINC:
- CinCor Pharma Shares Plunge after Analyst Downgrade
- CinCor Pharma price target lowered to $53 from $73 at Piper Sandler
- CinCor Nosedives after Baxdrostat Disappoints in Phase 2
- CinCor Pharma announces Phase 2 HALO trial does not meet primary endpoint
- CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences